These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36103378)

  • 1. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
    Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
    Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
    Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
    Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
    Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
    Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IQGAP1 Regulates Actin Polymerization and Contributes to Bleomycin-Induced Lung Fibrosis.
    Akter T; Atanelishvili I; Silver RM; Bogatkevich GS
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
    Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X
    Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity.
    Cutolo M; Gotelli E; Montagna P; Tardito S; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
    Arthritis Res Ther; 2021 Aug; 23(1):205. PubMed ID: 34344444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.
    Lindahl GE; Stock CJ; Shi-Wen X; Leoni P; Sestini P; Howat SL; Bou-Gharios G; Nicholson AG; Denton CP; Grutters JC; Maher TM; Wells AU; Abraham DJ; Renzoni EA
    Respir Res; 2013 Aug; 14(1):80. PubMed ID: 23915349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
    Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
    Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
    Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease.
    Ryu C; Walia A; Ortiz V; Perry C; Woo S; Reeves BC; Sun H; Winkler J; Kanyo JE; Wang W; Vukmirovic M; Ristic N; Stratton EA; Meena SR; Minasyan M; Kurbanov D; Liu X; Lam TT; Farina G; Gomez JL; Gulati M; Herzog EL
    Arthritis Rheumatol; 2020 Nov; 72(11):1905-1915. PubMed ID: 32602227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-155 in the progression of lung fibrosis in systemic sclerosis.
    Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
    Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target.
    Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA
    Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
    Cutolo M; Ruaro B; Montagna P; Brizzolara R; Stratta E; Trombetta AC; Scabini S; Tavilla PP; Parodi A; Corallo C; Giordano N; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
    Arthritis Res Ther; 2018 May; 20(1):77. PubMed ID: 29720235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology and bronchoalveolar lavage.
    Silver RM; Wells AU
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5(Suppl 5):v62-4. PubMed ID: 18784150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.
    Mendoza FA; Piera-Velazquez S; Farber JL; Feghali-Bostwick C; Jiménez SA
    Arthritis Rheumatol; 2016 Jan; 68(1):210-7. PubMed ID: 26360820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of endothelin inhibition on lung fibroblasts on patients with systemic sclerosis.
    Corrado A; Neve A; Costantino E; Palladino GP; Foschino Barbaro MP; Cantatore FP
    Minerva Med; 2013 Oct; 104(5):505-17. PubMed ID: 24101108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease.
    Lee SC; Huang CH; Oyang YJ; Huang HC; Juan HF
    J Transl Med; 2024 Jun; 22(1):600. PubMed ID: 38937794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.